Clinical Trials
28 trialsTotal Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
M.D. Anderson Cancer Center
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
University of Michigan Rogel Cancer Center
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Therapeutic Advances in Childhood Leukemia Consortium
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Therapeutic Advances in Childhood Leukemia Consortium
Allogeneic Stem Cell Transplant for CLL
M.D. Anderson Cancer Center
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
University of California, San Francisco
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Radiation Therapy Oncology Group
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Children's Oncology Group
Bu Flu TBI
OHSU Knight Cancer Institute
LCCC0510
UNC Lineberger Comprehensive Cancer Center
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Children's Oncology Group
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
M.D. Anderson Cancer Center
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Dana-Farber Cancer Institute